# Progentix Orthobiology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/progentix-orthobiology

- Industry: Healthcare
- Headquarters: Netherlands
- Website: www.progentix.com
- Latest round: Series A (Jan 22, 2008)
- Investors on record: 1

## About

Progentix Orthobiology BV specializes in developing innovative orthopedic solutions aimed at enhancing patient recovery and outcomes in bone regeneration and repair through advanced biological implants.Progentix Orthobiology BV is engaged in the research and development of orthopedic products, particularly synthetic bone substitutes. The company was acquired by NuVasive, Inc. in January 2009 for USD 15 mn, signaling a strategic pivot towards integrating advanced materials into surgical offerings. Progentix operates from the Netherlands, contributing to the global orthopedic market.Progentix Orthobiology BV focuses on producing innovative synthetic bone substitutes designed to improve healing and recovery in orthopedic surgeries. Their product offerings include advanced biologics tailored for use in various surgical procedures, catering to healthcare providers and institutions globally. The company aims to enhance surgical outcomes for conditions requiring bone regeneration and repair.Progentix Orthobiology BV generates revenue through the sale of its synthetic bone substitutes to healthcare providers and institutions. The pricing model involves product sales, with a focus on long-term partnerships and bulk purchase agreements from hospitals and surgical centers.In the upcoming years, Progentix Orthobiology BV plans to expand its product line by developing new synthetic bone substitutes aimed at various orthopedic applications. The company will target additional markets in Europe and Asia-Pacific by 2024, leveraging its recent acquisition by NuVasive, Inc. to enhance its development capabilities and market reach.

## Funding rounds

- Series A, Jan 22, 2008 — BioGeneration Ventures

## Investors

- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Series A